Valneva SE operates within the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Valneva SE with three other
pharmaceutical manufacturers in Europe:
New Nordic Healthbrands AB
sales of 452.61 million Swedish Kronor [US$51.58 million]
Eczacibasi Ilac Sanayi ve T.A.S.
(877.08 million Turkish Liras [US$115.82 million]
of which 85%
was Health), and
Science In Sport Plc
based in UNITED KINGDOM
(£50.57 million [US$65.51 million]
of which 51%
During the year ended December of 2019, sales at
Valneva SE were 126.20 million Euro (US$149.52 million).
increase of 11.6%
versus 2018, when the company's sales were 113.04 million Euro.
This was the fifth consecutive year of sales increases at Valneva SE
(and since 2014, sales have increased a total of 242%).
Sales of Commercialized Vaccines saw an increase
that was more than double the company's growth rate: sales were up
25.1% in 2019, from
103.65 million Euro to 129.67 million Euro.